Key facts
- Inbiomotion’s last known valuation is $20.7M (Jan 2021).
- It has raised $13.2M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Caixa Capital Risc, Asabys Partners, Institut Català de Finances, JV Risk Technologies, Alta Life Sciences — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Inbiomotion
- ·The full record, as it builds
Funding rounds
No funding rounds for Inbiomotion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inbiomotion
Developer of biomarkers designed to predict bone metastasis and improve the quality of life for breast cancer patients. The company's bio-markers are focused on the development of a diagnostic assay based on selective single-gene biomarkers that predict which patients are at risk of suffering bone-specific metastases from primary tumors, enabling healthcare providers to advance the clinical standard of care with personalized medicines.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2010
- Employees
- 10
- Website
- inbiomotion.com/
- Ownership
- Privately Held (backing)
Inbiomotion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inbiomotion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inbiomotion in its N-PORT filings yet. We sweep new filings monthly.